{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Seromucinous+Carcinoma&page=2", "query": { "condition": "Ovarian Seromucinous Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Seromucinous+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:24:06.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02101775", "title": "Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Serous Surface Papillary Adenocarcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 124, "start_date": "2014-07-21", "completion_date": "2027-03-06", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 8, "location_summary": "Duarte, California • South Pasadena, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101775" }, { "nct_id": "NCT00079430", "title": "Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brenner Tumor", "Fallopian Tube Cancer", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mixed Epithelial Carcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Undifferentiated Adenocarcinoma", "Primary Peritoneal Cavity Cancer", "Stage II Ovarian Epithelial Cancer", "Stage III Ovarian Epithelial Cancer", "Stage IV Ovarian Epithelial Cancer" ], "interventions": [ { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 113, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-07-22", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 17, "location_summary": "Orange, California • Chicago, Illinois • Iowa City, Iowa + 9 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079430" }, { "nct_id": "NCT02446600", "title": "Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Tumor", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Tumor", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 579, "start_date": "2016-03-28", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 337, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446600" }, { "nct_id": "NCT01504126", "title": "Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage II Fallopian Tube Cancer AJCC v6 and v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage III Fallopian Tube Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Propranolol Hydrochloride", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2012-03-09", "completion_date": "2019-08-15", "has_results": false, "last_update_posted_date": "2019-08-29", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 7, "location_summary": "Gilbert, Arizona • Houston, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01504126" }, { "nct_id": "NCT01275664", "title": "Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nausea and Vomiting", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Cystadenocarcinoma", "Stage II Ovarian Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Cancer", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Adjuvant Therapy", "type": "PROCEDURE" }, { "name": "Aprepitant", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Granisetron Transdermal Patch", "type": "DRUG" }, { "name": "Management of Therapy Complications", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2011-06", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-05-22", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 2, "location_summary": "Hinsdale, Illinois • Providence, Rhode Island", "locations": [ { "city": "Hinsdale", "state": "Illinois" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01275664" }, { "nct_id": "NCT00003385", "title": "Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 48, "start_date": "1999-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 7, "location_summary": "Honolulu, Hawaii • Iowa City, Iowa • Bethesda, Maryland + 3 more", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003385" }, { "nct_id": "NCT00217529", "title": "Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 3, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217529" }, { "nct_id": "NCT00002538", "title": "Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "laparoscopic surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1993-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-08-20", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002538" }, { "nct_id": "NCT00003644", "title": "Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "FEMALE", "summary": "Up to 120 Years · Female only" }, "enrollment_count": 571, "start_date": "1998-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2019-06-04", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 144, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 112 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003644" }, { "nct_id": "NCT00331422", "title": "Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "cytoreductive surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 7, "start_date": "2005-10", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-05-21T23:24:06.337Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00331422" } ] }